Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Yokota, Hiroki ^a,b   Hamamura, Kazunori ^a   Chen, Andy ^a   Dodge, Todd R ^a   Tanjung, Nancy ^a   Abedinpoor, Aysan ^a   Zhang, Ping ^a,b,c  

^a Indiana University Purdue University Indianapolis   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Osteoblasts; Osteoclasts; Osteoporosis; RANKL; Salubrinal

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ASCORBIC ACID; DEXAMETHASONE; GLYCEROL 2 PHOSPHATE; OSTEOCLAST DIFFERENTIATION FACTOR; SALUBRINAL; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CELL ADHESION; CELL FATE; CELL MATURATION; CELL MIGRATION; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GRANULOCYTE; LYMPHOCYTE TRANSFORMATION; MACROPHAGE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PROTEIN EXPRESSION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELL ADHESION; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CINNAMATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; STEM CELLS; THIOUREA;

EID: 84879489950     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-197     Document Type: Article

References (56)

1. Osteoporosis, frailty and fracture: implications for case finding and therapy. van den Bergh JP, van Geel TA, Geusens PP, Nat Rev Rheumatol 2012 8 163 172 10.1038/nrrheum.2011.217 22249162
2. Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A, Tanaka S, Tanaka Y, Hosoi T, Itoi E, Morimoto S, Itabashi A, Sugimoto T, Yamashita T, Gorai I, Mori S, Kishimoto H, Mizunuma H, Endo N, Nishizawa Y, Takaoka K, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H, J Bone Miner Metab 2011 29 37 43 10.1007/s00774-010-0188-x 20461422
3. PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis. Vercini F, Grimaldi F, Clin Cases Miner Bone Metab 2012 9 31 36 22783333
4. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A, Clin Ther 2012 34 521 536 10.1016/j.clinthera.2012.02.002 22440513
5. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. Yang Q, Jian J, Abramson SB, Huang X, J Bone Miner Res 2011 26 1188 1196 10.1002/jbmr.337 21308772
6. Benefits and risks of bisphosphonate therapy for osteoporosis. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miler PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT, J Clin Endocrinol Metab 2012 97 2272 2282 10.1210/jc.2012-1027 22523337
7. Sex steroids and the construction and conservation of the adult skeleton. Riggs BL, Khosla S, Melton LJ III, Endocr Rev 2002 23 279 302 10.1210/er.23.3.279 12050121
8. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Valverde P, Curr Med Chem 2008 15 284 304 10.2174/092986708783497274 18288984
9. PTHrP and breast cancer: more than hypercalcemia and bone metastases. Boras-Granic K, Wysolmerski JJ, Breast Cancer Res 2012 14 307 10.1186/bcr3129 22546075
10. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J, Science 2005 307 935 939 10.1126/science. 1101902 15705855
11. Salubrinal attenuates β-amyloid-induced neuronal death and microglial activation by inhibition of the NF-κB pathway. Huang X, Chen Y, Zhang H, Ma Q, Zhang YW, Xu H, Neurobiol Aging 2012 33 1007.e9 1007.e17 10.1016/j.neurobiolaging.2011.10.007
12. Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. Saito A, Ochiai K, Kondo S, Tsumagari K, Murakami T, Cavener DR, Imaizumi K, J Biol Chem 2011 286 4809 4818 10.1074/jbc.M110.152900 21135100
13. Salubrinal promotes healing of surgical wounds in rat femurs. Zhang P, Hamamura K, Jiang C, Zhang L, Yokota H, J Bone Miner Metab 2012 30 568 579 10.1007/s00774-012-0359-z 22610062
14. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. Li X, Ling W, Khan S, Yaccoby S, J Bone Miner Res 2012 27 1635 1648 10.1002/jbmr.1620 22460389
15. FSH directly regulates bone mass. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M, Cell 2006 125 247 260 10.1016/j.cell.2006.01.051 16630814
16. Estrogen deficiency and bone loss: an inflammatory tale. Weitzmann MN, Pacifici R, J Clin Invest 2006 116 1186 1194 10.1172/JCI28550 16670759
17. Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody. Shahnazari M, Wronski T, Chu V, Williams A, Leeper A, Stolina M, Ke HZ, Halloran B, Calcif Tissue Int 2012 91 50 58 10.1007/s00223-012-9610-9 22644321
18. A brief review of bone adaptation to unloading. Zhang P, Hammamura K, Yokota H, Genomics Proteomics Bioinf 2008 6 4 7 10.1016/S1672-0229(08)60016-9
19. Bone mineral density in spinal cord injury: an evaluation of the distal femur. Gaspar AP, Lazaretti-Castro M, Brandão CM, J Osteoporos 2012 2012 519754 22970408
20. Mechanisms of osteoporosis in spinal cord injury. Jiang SD, Jiang LS, Dai LY, Clin Endocrinol (Oxf) 2006 65 555 565 10.1111/j.1365-2265.2006.02683.x
21. Animal models for bone and joint disease. Low calcium diet-induced rat model of osteoporosis. Omi N, Ezawa I, Clin Calcium 2012 21 173 180
22. Effect of the supplementation of dietary rich phytoestrogens in altering the vitamin D levels in diet induced osteoporotic rat model. Chennaiah S, Vijayalakshmi V, Suresh C, J Steroid Biochem Mol Biol 2010 121 268 272 10.1016/j.jsbmb.2010.03.070 20362669
23. Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: A new therapy for human RANKL-dependent ARO. Lo Iacono N, Blair HC, Poliani PL, Marrella V, Ficara F, Cassani B, Facchetti F, Fontana E, Guerrini MM, Traggiai E, Schena F, Paulis M, Mantero S, Inforzato A, Valaperta S, Pangrazio A, Crisafulli L, Maina V, Kostenuik P, Vezzoni P, Villa A, Sobacchi C, J Bone Miner Res 2012 27 2501 2510 10.1002/jbmr.1712 22836362
24. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. Campbell GM, Ominsky MS, Boyd SK, Osteoporosis Int 2011 22 931 942 10.1007/s00198-010-1283-5
25. Animal models for bone and joint disease. RANKL-injected bone loss model. Yasuda H, Clin Calcium 2011 21 197 208 21289416
26. Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H, J Bone Miner Res 2009 24 1194 1205 10.1359/jbmr.090217 19257825
27. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents. Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W, J Pediatr Endocrinol Metab 2009 22 1099 1104 20333868
28. Osteoimmunology and the effects of the immune system on bone. Takayanagi H, Nat Rev Rheumatol 2009 5 667 676 10.1038/nrrheum.2009.217 19884898
29. Osteoporosis and RANKL signal. Nakamura M, Udagawa N, Clin Calcium 2011 21 1149 1155 21814019
30. Development and function of murine B cells lacking RANK. Perlot T, Penninger JM, J Immunol 2012 188 1201 1205 10.4049/jimmunol.1102063 22219325
31. Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. Mun SH, Won HY, Hernandez P, Aguila HL, Lee SK, J Bone Miner Res 2013 28 948 959 10.1002/jbmr.1787 23044992
32. DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Droxmeyer HE, Kappes F, Mor-Vaknin N, Legendre M, Kinzforql J, Cooper S, Hangoc G, Markovitz DM, Stem Cells Dev 2012 21 1449 1454 10.1089/scd.2011.0451 21943234
33. Exercise increases the frequency of circulating hematopoietic progenitor cells, but reduces hematopoietic colony-forming capacity. Kroepfl JM, Pekovits K, Stelzer I, Fuchs R, Zelzer S, Hofmann P, Sedlmayr P, Dohr G, Wallner-Liebmann S, Domej W, Muller W, Stem Cells Dev 2012 21 2915 2925 10.1089/scd.2012.0017 22616638
34. c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions. He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC, PLoS One 2012 7 46900 10.1371/journal.pone.0046900 23144792
35. Genetic background influences fluoride's effects on osteoclastogenesis. Yan D, Gurumurthy A, Wright M, Pfeiler TW, Loboa EG, Everett ET, Bone 2007 41 1036 1144 10.1016/j.bone.2007.07.018 17936699
36. SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Broxmeyer HE, Mejia JA, Hangoc G, Barese C, Dinauer M, Cooper S, Stem Cells Dev 2007 16 589 596 10.1089/scd.2007.0044 17784832
37. Role of cell-matrix interactions in osteoclast differentiation. McHugh KP, Shen Z, Crotti TN, Flannery MR, Fajardo R, Bierbaum BE, Goldring SR, Adv Exp Med Biol 2007 602 107 111 10.1007/978-0-387-72009-8-14 17966395
38. p85α regulates osteoblast differentiation by cross-talking with the MAPK pathway. Wu X, Chen S, Orlando SA, Yuan J, Kim ET, Munugalavadla V, Mali RS, Kapur R, Yang FC, J Biol Chem 2011 286 13512 13521 10.1074/jbc.M110.187351 21324896
39. DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice. Abdallah BM, Ditzel N, Mahmood A, Isa A, Traustadottir GA, Schilling AF, Ruiz-Hidalgo MJ, Laborda J, Amling M, Kassem M, J Bone Miner Res 2011 26 1457 1471 10.1002/jbmr.346 21308776
40. Osteoclast fusion and fission. Jansen ID, Vermeer JA, Bloemen V, Stap J, Everts V, Calcif Tissue Int 2012 90 515 522 10.1007/s00223-012-9600-y 22527205
41. Critical role of filamin-binding LIM protein 1 (FBLP-1)/migfilin in regulation of bone remodeling. Xiao G, Cheng H, Cao H, Chen K, Tu Y, Yu S, Jiao H, Yang S, Im HJ, Chen D, Chen J, Wu C, J Biol Chem 2012 287 21450 21460 10.1074/jbc.M111.331249 22556421
42. Effects of microgravity on osteoclast bone resorption and osteoblast cytoskeletal organization and adhesion. Nabavi N, Khandani A, Camirand A, Harrison RE, Bone 2011 49 965 974 10.1016/j.bone.2011.07.036 21839189
43. The RANKL/RANK/OPG pathway. Boyce BF, Xing L, Curr Osteoporos Rep 2007 5 98 104 10.1007/s11914-007-0024-y 17925190
44. Bone density and hyperlipidemia: the T-lymphocyte connection. Graham LS, Tintut Y, Parhami F, Kitchen CM, Ivanov Y, Tetradis S, Effros RB, J Bone Miner Res 2010 25 2460 2469 10.1002/jbmr.148 20533376
45. RANKL-RANK interaction in immune regulatory systems. Akiyama T, Shinzawa M, Akiyama N, World J Orthop 2012 3 142 150 10.5312/wjo.v3.i9.142 23173110
46. Cadherin-11 regulates fibroblast inflammation. Chang SK, Noss EH, Chen M, Gu Z, Townsend K, Grenha R, Leon L, Lee SY, Lee DM, Brenner MB, Proc Natl Acad Sci U S A 2011 108 8402 8407 10.1073/pnas.1019437108 21536877
47. Porphyromonas gingivalis induces RANKL in T-cells. Belibasakis GN, Reddi D, Bostanci N, Inflammation 2011 34 133 138 10.1007/s10753-010-9216-1 20446027
48. Glucose activates a protein phosphatase-1-mediated signaling pathway to enhance overall translation in pancreatic beta-cells. Vander Mierde D, Scheuner D, Quintens R, Patel R, Song B, Tsukamoto K, Beullens M, Kaufman RJ, Bollen M, Schuit FC, Endocrinology 2007 148 609 617 17082262
49. Both transcriptional regulation and translational control of ATF4 are central to the integrated stress response. Dey S, Baird TD, Zhou D, Palam LR, Spandau DF, Wek RC, J Biol Chem 2010 285 33165 33174 10.1074/jbc.M110.167213 20732869
50. Deficiency of αB crystallin augments ER stress-induced apoptosis by enhancing mitochondrial dysfunction. Dou G, Sreekumar PG, Spee C, He S, Ryan SJ, Kannan R, Hinton DR, Free Radic Biol Med 2012 53 1111 1122 10.1016/j.freeradbiomed.2012.06.042 22781655
51. Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. Hamamura K, Tanjung N, Yokota H, J Bone Miner Metab 2013 in press
52. The role of NFAT in osteoclast formation. Takayanagi H, Ann NY Acad Sci 2007 1116 227 237 10.1196/annals.1402.071 18083930
53. Osteoporosis regulation by salubrinal through eIF2 α mediated differentiation of osteoclast and osteoblast. He L, Lee J, Jang JH, Sakchaisri K, Hwang J, Cha-Molstad HJ, Kim KA, Ryoo IJ, Lee HG, Kim SO, Soung NK, Lee KS, Kwon YT, Erikson RL, Ahn JS, Kim BY, Cell Signal 2013 25 552 560 10.1016/j.cellsig.2012.11.015 23178987
54. MafB negatively regulates RANKL-mediated osteoclast differentiation. Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK, Lee SY, Kim N, Blood 2007 109 3253 3259 10.1182/blood-2006-09-048249 17158225
55. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkiv LB, Takayanagi H, Kamijo R, Nat Med 2009 15 1066 1071 10.1038/nm.2007 19718038
56. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, Miyamoto K, Hao W, Yoshida S, Morioka H, Chiba K, Kato S, Tokuhisa T, Saitou M, Toyama Y, Suda T, Miyamoto T, J Exp Med 2010 207 751 762 10.1084/jem.20091957 20368579